<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606409</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00008718/1548</org_study_id>
    <nct_id>NCT02606409</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients</brief_title>
  <acronym>DEXsedation</acronym>
  <official_title>Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine, a central and peripheral α2-receptor agonist distinct from GABA receptor for
      benzodiazepines and propofol, has been approved by the US Food and Drug Administration only
      for use up to 24 h in mechanically ventilated patients. The investigators aim to compare
      dexmedetomidine with propofol for sedation &gt;24h in poly traumatized mechanically ventilated
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The importance of optimizing the levels of sedation in critical care has been increasingly
      recognized. Many intensive care experts are focusing on maintaining a targeted ''ideal''
      sedation level according to the individual patient's condition to avoid adverse events such
      as prolonged mechanical ventilation, respiratory depression, pneumonia, delirium,
      psychological problems, and increased treatment costs resulting from over sedation.
      Dexmedetomidine is a selective alpha-2-adrenoceptor agonist. It exerts both sedative and
      analgesic effects via mechanisms different from other sedatives such as midazolam and
      propofol, and provides sedation characterized by prompt response to stimuli with no
      respiratory depression. The investigators aim to compare dexmedetomidine with propofol for
      sedation &gt;24h in poly traumatized mechanically ventilated patients. The investigators will
      perform a prospective, single center trial to investigate the safety and efficacy of
      dexmedetomidine for long-term sedation in poly traumatized mechanically ventilated ICU
      patients, in comparison with propofol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of time with in the target sedation range of Richmond Agitation Sedation Scale-3-0</measure>
    <time_frame>3 days</time_frame>
    <description>sedation goal is to maintain Richmond Agitation Sedation Scale from -3 up to 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum BUN</measure>
    <time_frame>3-days</time_frame>
    <description>Assessment of the serum level of BUN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine.</measure>
    <time_frame>3-days</time_frame>
    <description>Assessment of the serum level of creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>3- days.</time_frame>
    <description>systolic blood pressure is measured every hour for 3- days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>3- days.</time_frame>
    <description>diastolic blood pressure is measured every hour for 3- days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>3- days.</time_frame>
    <description>heart rate is recorded every hour for 3-days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine intravenous sedation at 0.2-0.7 µg/kg/h for &gt;24h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol sedation at 10-70µg/kg/h for &gt;24h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol sedation at a starting dose of 10-70 µg/kg/hour.</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Deprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Endotracheal Intubation

          -  Mechanical ventilation

          -  Poly traumatized

          -  ICU patients and estimated duration of sedation&gt;24 h.

        Exclusion Criteria:

          -  Patients with serious trauma in the central nervous system,

          -  with bleeding probably requiring surgical hemostasis,

          -  drug overdose within the last 30 days before study entry,

          -  pregnancy/lactation,

          -  contraindication to alpha-2-adrenoceptor agonists or antagonists,

          -  cardiovascular disease,

          -  conduction disturbances or difficulty in data collection or completing the study
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala S Abdel-Ghaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisstant professor in Anesthesia and intensive care department, faculty of medicine, Assiut university, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospitals</name>
      <address>
        <city>Assiut</city>
        <state>Assiut governorate</state>
        <zip>715715</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>August 20, 2016</last_update_submitted>
  <last_update_submitted_qc>August 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hala Saad Abdel-Ghaffar</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

